Cocaine is a widely abused substance with psychostimulant effects that are attributed to inhibition of the dopamine transporter (DAT). We present molecular models for DAT binding of cocaine and cocaine analogs constructed from the high-resolution structure of the bacterial transporter homolog LeuT. Our models suggest that the binding site for cocaine and cocaine analogs is deeply buried between transmembrane segments 1, 3, 6 and 8, and overlaps with the binding sites for the substrates dopamine and amphetamine, as well as for benztropine-like DAT inhibitors. We validated our models by detailed mutagenesis and by trapping the radiolabeled cocaine analog [ 3 H]CFT in the transporter, either by cross-linking engineered cysteines or with an engineered Zn 21 -binding site that was situated extracellularly to the predicted common binding pocket. Our data demonstrate the molecular basis for the competitive inhibition of dopamine transport by cocaine.
three different tricyclic antidepressants, clomipramine, imipramine and desimipramine, which target NET and SERT with high affinity and were found to have low affinity for LeuT as well 13, 14 . The structures identified an inhibitor-binding site situated in an extracellular vestibule above the substrate-binding site where binding of the inhibitor apparently stabilizes the external gate in a closed conformation, resulting in noncompetitive inhibition of substrate transport 13, 14 . The structures raise the question of whether this is a binding mode that can be generalized to the mammalian transporters and to other classes of inhibitors.
Previous mutagenesis studies have attempted to define cocainerecognition sites in the DAT, resulting in the identification of numerous residues that affect cocaine binding on mutation (for review, see refs. 15, 16) . Molecular models of the binding site for cocaine have been proposed on the basis of these data 15, 16 ; however, in the absence of insight into the accurate tertiary structure of DAT, it has been difficult to differentiate between direct and indirect effects of mutations. Studies using photoreactive cocaine analogs have suggested approximate binding regions in the DAT 17 , but without appropriate molecular models it is still difficult to make accurate predictions about the binding site from these data. Thus, the precise nature of the cocainebinding site and its relationship to the substrate-binding site have remained uncertain.
We present here, on the basis of the LeuT structure and a previously reported sequence alignment 10 , molecular models of cocaine and cocaine analog binding to the DAT, in comparison with that of dopamine, amphetamine and DAT inhibitors of the benztropine class. In these models, which were validated by detailed mutagenesis analysis and intramolecular cross-linking strategies, cocaine and its analogs occupy a binding pocket that is deeply buried in the transporter structure, which overlaps with that of dopamine, but is clearly distinct from that observed for antidepressant binding to LeuT.
RESULTS
Binding models for dopamine and the cocaine analog CFT To achieve insight into the molecular basis for the interaction between cocaine and DAT, we developed a molecular model of DAT from the high-resolution structure of the bacterial NSS member LeuT (Protein Data Bank accession code 2A65) 12 and a recently refined alignment of NSS proteins 10 . The ligand-docking protocol 18 was validated with the successful redocking of leucine into LeuT, which reproduced the crystal structure. Thus, the lowest-energy model identified by the set of criteria established for the docking protocol used throughout had a r.m.s. deviation of B1 Å relative to the crystal structure. Notably, this low-energy binding mode was populated multiple times during the docking simulation, indicating that the protocol yields converged solutions. Following this same protocol, we determined the binding modes of dopamine and the cocaine analog CFT ((-)-2b-carbomethoxy-3b-(4-fluorophenyl)tropane or WIN 35, 428 ) in the DAT model. CFT has pharmacological properties that are similar to those of cocaine, and was chosen for its high affinity and structural rigidity (Fig. 1b) 19 . The models resulting from the initial docking were refined with molecular dynamics simulations of the complex immersed in an environment that included water and the membrane in explicit atomic details.
The final docking models revealed binding sites for dopamine and CFT in the center of DAT that were composed of residues in transmembrane domains (TMD) 1, 3, 6 and 8. Despite the differences in molecular size and structure between dopamine and CFT, we found that most of the protein side chains that interact with CFT were identical with those in dopamine binding ( Fig. 1 and Table 1 ). A recent modeling study proposed a similar binding mode for dopamine 20 . The protonated amine of dopamine formed a salt-bridge with the Asp79 side chain (Fig. 1c) . Our models also predicted a polar interaction between the amine of CFT and Asp79 (Fig. 1d) . The aromatic ring of dopamine and the tropane ring of CFT interacted with hydrophobic and aliphatic residues in TMD 1 (Phe76), 3 (Val152) and 6 (Phe320 [omitted for clarity], Phe326, Val328) (Fig. 1c,d ). Dopamine further engaged in hydrogen bonds with exposed backbone carbonyls of the unwound regions of TMDs 1 and 6 ( Fig. 1c and Table 1 ) and the N-methyl substituent of CFT was inserted in between TMDs 1 and 6, where it interacted with Phe76 and with the backbone of TMD 6 ( Fig. 1d and Table 1 ). The para-hydroxyl group of the catechol ring in dopamine interacted the with backbone atoms of Ser149 and Val152, whereas the meta-hydroxyl group interacted with Ser422, Ala423 and G425. In the case of CFT, these residues interacted with the halogenated phenyl ring (Fig. 1c,d and Table 1 ).
Important differences also became apparent in the binding sites of the two ligands. One marked difference involved the network of interactions surrounding Tyr156 in TMD 3. Notably, this residue is 100% conserved in all NSS transporters 10 , and, in LeuT, the hydroxyl group of the tyrosine binds the carboxylate group of leucine 12 . In the dopamine-binding model, the network of interactions involving Tyr156 included an aromatic-aromatic stacking interaction with the
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catechol ring of dopamine, a hydrogen bond between the hydroxyl group and Asp79 in TMD 1 and a hydrophobic-aromatic interaction with the side chain of Leu80 on the extracellular side (Fig. 1c) . CFTalso interacted with Tyr156 through the 2b-methylester substituent (Fig. 1d) in the CFT-binding model, but stabilized a different conformation of the side chain. This reorientation disrupted the hydrogen bond between Tyr156 and the key Asp79 residue (Fig. 1c,d ). Another key difference between CFT and dopamine binding involved a unique interaction between the nitrogen of Asn157 and the fluoride atom of CFT ( Fig. 1d and Table 1 ).
Experimental validation of binding models
We sought to experimentally validate the binding models of CFT and dopamine by verifying commonalities and differences between their binding modes. Previous reports have suggested a role for Asp79 in binding both CFT and dopamine 21, 22 , which is consistent with the interactions that we observed between the protonated amines of the ligands and this residue (Fig. 1c,d (Fig. 1c,d ). It has been suggested previously that this residue is involved in cocaine binding from analysis of bovine and human DAT chimeras 24 and by analysis of the corresponding residue in SERT (Ile172) 25 . To further assess the role of this position in DAT, we mutated the residue to alanine (V152A), isoleucine (V152I) and methionine (V152M). Consistent with our predictions, the K M value for [ 3 H]dopamine uptake increased 5-18-fold in these mutants ( Fig. 2a and uptake-inhibition assay confirmed that there was a more pronounced effect on CFT binding of the methionine substitution as compared with V152A and V152I ( Fig. 2b and Supplementary Table 1) . For Tyr156, which is situated one a-helical turn above Val152 in TMD 3, our models predicted an essential role for the aromatic ring in binding both dopamine and CFT (Fig. 1c,d) Supplementary Fig. 1 online) . Thus, the lack of measurable binding and uptake was probably the result of disruption of critical interactions with the ligands and not of impaired folding and retention in the endoplasmic reticulum. Note that previous studies in SERT and in the GABA transporter-1 (GAT-1) have suggested that this highly conserved tyrosine is involved in substrate binding in these transporters as well 26, 27 . According to our model, Val328 in TMD 6 is another important residue in the hydrophobic pocket that surrounds the ligands, and thus its mutation would be predicted to affect both recognition of CFT and dopamine (Fig. 1c, not shown). The differences in effects of V328I on dopamine and CFT recognition were analyzed in the structural context with molecular dynamics simulations of the V328I mutant. We found that dopamine could accommodate the added bulk in V328I through a small shift in the position of the ligand that was made possible by its relatively small size; in contrast, CFT occupied a larger portion of the binding-site volume, and its interactions did not permit such a shift to avoid the steric clash (data not shown).
Finally, we analyzed Ser422 (situated in TMD 8), which, according to our model, interacts with the hydroxyls of the catechol ring in dopamine and the aromatic ring in CFT (Fig. 1c,d and Table 1 To investigate the predicted differences between the binding modes of dopamine and CFT, we also mutated Tyr156 to phenylalanine (Y156F). The removal of this hydroxyl group would be predicted to destabilize the dopamine-binding pocket by disrupting the hydrogen bond between Tyr156 and Asp79, while preserving the CFT binding scheme in which this hydrogen bond is already missing (Fig. 1c, Tables 2 and 3 ).
In the dopamine-binding model, Tyr156 not only formed a hydrogen bond with Asp79, but also made a hydrophobic-aromatic interaction with Leu80 in TMD 1 (Fig. 1c) . Accordingly, we predicted that mutation of Leu80 would destabilize Tyr156, and thereby selectively impair the interaction of DAT with dopamine, as in Y156F. Indeed, mutation of Leu80 to Cys (L80C) decreased the potency of dopamine, whereas [ 3 H]CFT binding was unaffected ( Supplementary Fig. 2 and Supplementary Table 4 online). [ 3 H]dopamine uptake was not measurable in L80C (data not shown), which is consistent with the decreased potency of dopamine to inhibit [ 3 H]CFT binding, but which also suggests an additional effect on uptake efficacy as compared with Y156F. Note that mutation in SERT and GAT-1 of the residues corresponding to Leu80 also resulted in marked impairment of substrate transport, supporting a possible general role of this position in NSS proteins 28, 29 .
As a final test to validate the differences between the dopamine-and CFT-binding modes, we mutated Asn157 in TMD 3, which forms a polar interaction with the fluorine substituent of CFT and therefore has the only predicted unique side chain interaction with this compound compared with the dopamine-binding mode ( Fig. 1d and Table 1 ). Indeed, the mutation (N157C) did not affect the K M value for [ 3 H]dopamine uptake, but the K D for [ 3 H]CFT binding was increased by B15-fold, supporting the specific interaction in the model (Fig. 2c-f and Supplementary Table 1) .
A buried CFT-binding pocket is supported by cross-linking
To exclude indirect effects from the inferences suggested by the mutagenesis and to further validate the buried position of the CFT binding site, we attempted to trap radiolabeled CFT in its binding pocket by introducing structural constraints at positions predicted to lie extracellular to the bound ligand. First, we undertook to engineer a Zn 2+ -binding site, as such constructs have been used previously to impose intramolecular structural constraints in membrane proteins, including this transporter class [30] [31] [32] . Our model predicted that a bidentate (two coordinating residues) Zn 2+ -binding site might be formed above the CFT binding pocket between position 80 (Leu80) and 159 (Ile159) if these positions were substituted with a histidine and a cysteine, respectively (Fig. 3a) . According to the model, Zn 2+ would coordinate His80 and Cys159 in a tetrahedral conformation with Cys-S-to-Zn 2+ distances of 2.6 Å , and His-N-to-Zn 2+ distances of 2.2 Å . Binding of Zn 2+ to this site should constrain the His80 side chain and place the imidazole ring immediately above the CFT-binding pocket, thereby potentially restricting release of bound CFT (Fig. 3a) . It is interesting to note that the Zn 2+ -binding site position corresponded to an extracellular vestibule that was recently shown to represent a noncompetitive binding site for antidepressants in LeuT 13,14 (illustrated by a spherical model of clomipramine bound to LeuT; Fig. 3a) . Thus, the two residues in LeuT corresponding to Leu80 and Ile159 (Leu25 and Ile111) both line this allosteric site 13, 14 , making the binding of Zn 2+ and of the antidepressant mutually exclusive (Fig. 3a) .
To validate the model experimentally, we generated the Zn 2+ -binding double mutant L80H-I159C in a DAT background (E2C H193K) in which endogenous Zn 2+ sensitivity was eliminated by mutation of His193 to lysine 30, 33 . Two extracellular cysteines (Cys90 and Cys306) were also mutated in this construct, thereby rendering the transporter insensitive to modification with extracellularly applied sulfhydryl-reactive reagents 33 . This background was chosen to allow direct comparison with the cysteine cross-linking experiments described below (see Supplementary Note online). Consistent with the model, application of 100 mM Zn 2+ to cells expressing the resulting construct E2C H193K-L80H-I159C caused a decrease in the off rate of prebound [ 3 H]CFT by Bfourfold (Fig. 3a) . In contrast, Zn 2+ had no effect on and L80K-I159C (all made in E2C H193K ) (Fig. 3a) . Unfortunately, we were unable to perform uptake experiments in E2C H193K-L80H-I159C because of the importance of Leu80 for dopamine binding (Supplementary 
In a second strategy we used the bifunctional sulfhydryl-reactive cross-linking reagent 1,3-propanediyl bismethane-thiosulfonate (MTS-3-MTS) to crosslink cysteine residues with Cb atoms separated by o10 Å . We introduced cysteines in the background construct E2C (see Supplementary Note) at positions 84 (Trp84) and 159 (Ile159), which would be just above the CFT binding site with a predicted distance of 8.5 Å between the Cb atoms of Cys84 and Cys159 (Fig. 3b) . In addition, these positions have been cross-linked in the related GAT-1 (ref. 34 ). We observed a 4threefold decrease in [ 3 H]CFT off-rate on treatment of the resulting double mutant E2C W84C-I159C with 0.5 mM MTS-3-MTS after prebinding of [ 3 H]CFT (Fig. 3b) , consistent with cross-linking of the two engineered cysteines and subsequent partial trapping of [ 3 H]CFT in its binding site. There was no effect of MTS-3-MTS on [ 3 H]CFT dissociation in the background construct E2C or in the control mutants W84C, I159C, W84C-I159A or W84A-I159C (all made in E2C; Fig. 3b) . We also attempted cross-linking in E2C W84C-I159C mutants with copper phenanthroline and cadmium; however, we did not observe an effect of these, suggesting that the two cysteines did not come sufficiently close to form a disulfide bridge or to be cross-linked by cadmium. Finally, we used the bulky MTS reagent benzocaine-methanethiosulfonate (BZ-MTS) to test whether imposing a simple steric hindrance above the binding pocket was sufficient to slow [ 3 H]CFT dissociation (Fig. 3c) . Consistent with this notion, BZ-MTS (0.5 mM) markedly decreased the off-rate of prebound [ 3 H]CFT in both E2C I159C and in E2C W84C (Fig. 3c) , whereas no effect on [ 3 H]CFT dissociation was observed in the background construct E2C or in the control mutants I159A or W84A (both made in E2C; Fig. 3c ). Although the effect of the reagents on CFT dissociation was similar to that of Zn 2+ , we were unable to reliably assess the effect of MTS-3-MTS and BZ-MTS pretreatment on [ 3 H]CFT association because of interference from cysteines still present in the E2C background (Supplementary Note).
Binding modes for cocaine, amphetamine and benztropines
The binding models of CFT and dopamine were first compared with that of cocaine, which was predicted to bind similarly to CFT (Fig. 4) . Consistent with this, we observed no changes in affinity for cocaine in Y156F as determined in [ 3 H]CFT competition binding experiments and [ 3 H]dopamine uptake-inhibition experiments, as predicted by the disruption of the Tyr156-Asp79 hydrogen bond by cocaine binding (Fig. 4a and Supplementary Tables 2 and 3 ). This similarity in binding modes was further supported measurements of the ability of cocaine to inhibit [ 3 H]dopamine uptake in V152M, V328I and S422A mutants (Supplementary Table 1 ). Mutation of Asn157 (N157C) also affected cocaine binding (fivefold decrease in potency; Supplementary  Table 1) ; however, the interaction of CFT was through the fluorine substituent (Fig. 1d) , whereas the interaction of cocaine was through the aromatic ring (Fig. 4a) . Calculation of the nonbonded interaction energy between the side chain of Asn157 and the ligands agreed with these data, with CFT showing a favorable interaction energy of B1.9 kcal mol -1 , cocaine showing 0.8 kcal mol -1 and dopamine having virtually no interaction (B0.1 kcal mol -1 ).
We also compared the binding models of dopamine, CFT and cocaine with those of a series of structurally diverse DAT ligands (Fig. 5a) . We found it interesting that the Tyr156-Asp79 hydrogen bond that we observed in dopamine binding was preserved in all modeled complexes except those of cocaine and CFT (Fig. 4 and Supplementary Fig. 3 online) . Accordingly, it would be expected that the removal of the hydrogen bond by mutation of Tyr156 to phenylalanine would affect binding for all these ligands, as we observed for dopamine. Consistent with this, we observed, on the basis of [ 3 H]CFT competition binding experiments, 19-and 6-fold decreases in affinity for the substrates amphetamine and 3,4-methylenedioxy-N-methylamphetamine ('ecstasy'), respectively (Fig. 4d, Supplementary Fig. 3 and Supplementary Table 4) . For three different benztropines, including benztropine itself, JHW007 and MFZ 2-71 (refs. 35,36) , the experimental observations were also consistent with the models; hence, the binding affinities assessed in mutation of Tyr156 to phenylalanine, supporting the idea that the Asp79-Tyr156 hydrogen bond is important for interaction (Fig. 4f,  Supplementary Fig. 3 and Supplementary Table 3 ). The analog JHW007 was of particular interest to us, as it has been shown to fully antagonize the response to cocaine in behavioral models 36 . Note that we observed mainly similar effects when assessing [ 3 H]dopamine uptake-inhibition potency in Y156F as compared with calculating affinity from [ 3 H]CFT competition binding, although the effects appeared to be more modest for MFZ 2-71 and methylenedioxy-Nmethylamphetamine ( Supplementary Tables 2 and 3) .
The stability and time-dependent behavior of the discriminant Tyr156-Asp79 hydrogen bond was explored with molecular dynamics simulations. All of the modeled complexes were simulated for 1 ns at 310 K, and the average distance between the oxygen atoms of Tyr156 and Asp79 was monitored in the second (500 ps) half of the trajectory. As illustrated by plotting the observed affinity ratios (K I of Y156F:K I of wild type) against the donor-acceptor distance of the hydrogen-bond (Fig. 5b) , the hydrogen bond was continuously present (distance o3.5Å ) in all trajectories, except for those of CFT and cocaine, in agreement with the inference from experimental data. Finally, the CFT and dopamine models were simulated in a realistic solvated membrane environment, showing that disruption of the Tyr156-Asp79 hydrogen bond was associated with water permeating deep into the CFT-binding site (Fig. 5c) . In the dopamine-bound state, however, the Tyr156-Asp79 hydrogen bond effectively closed the binding site from the extracellular side and prevented water from entering (Fig. 5c) . Notably, the increased hydration stabilized the CFT-binding site and thereby compensated for the loss of intramolecular interactions. This explains mechanistically the unaltered affinity of CFT seen on removal of the Tyr156-Asp79 hydrogen bond in Y156F, and also suggests how the recently shown ability of cocaine and CFT, but not dopamine, to stabilize an open, outward-facing conformation of the transporter can be achieved 37 .
DISCUSSION
The molecular mode of interaction of cocaine with DAT has long been the subject of speculation 7, 15, 16 . In particular, it has been debated whether or not the cocaine-binding site in DAT overlaps with that of dopamine. If inhibition of dopamine uptake by cocaine is the result of an allosteric mechanism, it would be possible, at least in theory, to generate a cocaine antagonist for treatment of cocaine addiction that might block cocaine binding without affecting dopamine transport 38 . However, if the binding sites for the two compounds are overlapping, then the challenge would be greater, and of a different nature. In support of an allosteric mechanism, previous studies have identified several residues, which, on mutation, generate differentiated effects on cocaine and dopamine binding 5, 15, 16, 33, 38 . One study supporting an allosteric mechanism showed that mutation of three residues in the external part of TMD 2 results in a cocaine-insensitive DAT that is still capable of transporting dopamine 39 . However, an analysis of the LeuT structure suggested that the cocaine antagonizing effects of these mutations were probably the result of conformational changes in TMD 2, which indirectly might affect its binding to another site, such as the canonical substrate-binding site 40 . Of further interest, we previously identified a mutation (Y335A) in DAT that leads to a 4100-fold decrease in cocaine affinity, while causing an increase in dopamine affinity 41 . Nonetheless, experimental data, as well as the fact that the residue is located in an intracellular loop, strongly suggest that the marked decrease in affinity for cocaine and analogs is the result of an altered conformational equilibrium of DAT toward an inward facing conformation, rather than because of disruption of a direct interaction between the mutated residue and the ligand 33 .
The bacterial NSS member LeuT was recently crystallized in complex with three different antidepressants, clomipramine, imipramine and desipramine 13, 14 . These compounds show low affinity for the LeuT, in addition to being potent inhibitors of SERT and/or NET, which are closely related to DAT 8 . The new LeuT structures identified a noncompetitive binding site for the antidepressants in an extracellularfacing vestibule situated above the occluded substrate-binding site, where the compounds are thought to stabilize the external gate in a closed conformation, and thereby noncompetitively inhibit substrate transport 13, 14 . The new structures raised the question of whether they describe a binding mode for inhibitors that can be generalized to mammalian NSS proteins, as well as to other classes of NSS inhibitors such as cocaine. Hence, the allosteric nature of antidepressant binding to LeuTrenewed interest in an allosteric mechanism for cocaine in DAT.
Our current findings strongly argue against this possibility by showing clear evidence that cocaine and related inhibitors do not bind in the vestibule occupied by antidepressants in LeuT. Instead, our data suggest a binding site for cocaine and its analogs that is buried deep in between TMDs 1, 3, 6 and 8, and that overlaps extensively with that of dopamine ( Fig. 1 and Table 1 ). Our ligand-binding models were substantiated by mutation of residues predicted to interact with both ligands, as well as of residues predicted to selectively interact with either dopamine or cocaine/CFT. The buried nature of the cocaine/CFTbinding site was further confirmed by the effects of chemical cross-links or of steric block at engineered positions aligned with those that form the noncompetitive binding site for antidepressants in LeuT (Fig. 3) . It is noteworthy that not all mutations in the transmembrane core affected dopamine and/or cocaine/CFT binding. Table 4 ), lending additional support to the specificity of our observations. In addition, we mutated Leu147 (L147C), positioned in TMD 3, right below the binding site, without observing any change in either dopamine or CFT affinity (data not shown). Previous studies using photoreactive cocaine analogs are consistent with our data. Recently, it was shown that the photoreactive cocaine analog [ 125 I]RTI 82 incorporated into TMD 6 (ref. 17) , which is an important part of the cocaine-binding site in the models presented here. Together with these previous findings, our results provide strong evidence that cocaine and its analogs are true competitive inhibitors. It is interesting to note that the binding site in SERT for cocaine is probably similar to that seen in DAT. Mutation of Asp98 in SERT to glutamate (corresponding to Asp79 in TMD 1 of DAT), for example, markedly impairs cocaine binding 42 . Similarly, it has been shown that mutation of Ile172 in SERT (Leu152 in DAT) markedly decreases cocaine affinity 25, 26 , paralleling our observations in the corresponding DAT mutation (Fig. 2a,b) .
Molecular models of DAT with dopamine or cocaine bound have been generated before the LeuT structure became available. These models were constructed either by positioning the twelve predicted helices relative to one another on the basis of information from existing mutagenesis data or by using available projection structures of other transport proteins, such as the E. Coli Na + /H + exchanger NhaA 43, 44 . Consistent with the present findings, these models predicted the existence of a central hydrophobic cavity harboring the cocaine-and dopamine-binding sites. Some residues that were shown in this study to interact with the ligands were also suggested to interact in these earlier models. Specifically, Asp79 in TMD 1 was predicted to form an ionic interaction with the protonated amine of dopamine, as well as with the amine of CFT/cocaine 43 . Moreover, Phe76 was predicted to line the hydrophobic binding cavity 23, 43 . Nonetheless, there are also substantial differences, with several interactions diverging between the earlier models and our present LeuT-based models. These differences are not surprising given the major differences between the structural organization of LeuT and, for example, NhaA; hence, although this protein is also a 12-transmembrane segment ion-coupled transport protein, it is not as valid a template for modeling of DAT or other mammalian NSS proteins as LeuT. In conclusion, accurate mapping of the cocaine-and dopamine-binding sites in DAT has not been feasible before the LeuT structure became available as a modeling template.
We modeled and analyzed inhibitors of the benztropine class. These inhibitors were also suggested to bind in the central cavity, and thus to a binding site overlapping with that of dopamine. In contrast to cocaine/ CFT, however, they bound in a way that preserved the Asp79-Tyr156 hydrogen bond, and thereby formed a closed binding pocket. Notably, we have recently assessed conformational changes in DAT promoted by different benztropine and cocaine analogs by determining reactivity of a cysteine inserted in position 159, which is believed to be accessible in the outward facing conformation when the extracellular gate is open and inaccessible when the gate is closed 37 . These data showed that, although cocaine and its analogs probably stabilize the open outwardfacing conformation, benztropines probably stabilize the closed conformation. This is consistent with the present binding models and is supported by simulations of the CFT binding model in a realistic membrane environment showing water permeating deep into the CFT-binding site (Fig. 5) . Of note, several benztropine analogs are less effective than cocaine as behavioral stimulants, despite having similar or higher affinity and selectivity for the DAT than cocaine 36, 45 . Furthermore, one of the benztropines, JHW 007, was found to potently antagonize the behavioral effects of cocaine 36 . It is tempting, therefore, to speculate that the different binding configurations between cocaine and benztropines could contribute to their different pharmacological profiles, and therefore offer structureinformed hypotheses for molecular mechanisms underlying psychostimulant action.
In summary, we present here, to the best of our knowledge, the first comprehensive and experimentally validated model of substrate and inhibitor binding to the DAT, in the context of the high-resolution structure of the bacterial transporter homolog LeuT. Our data provide strong evidence that substrates and inhibitors, including widely abused psychostimulants such as cocaine and amphetamine, occupy an essentially similar binding pocket that is buried deep in the DAT molecule and corresponds to the substrate-binding site in the LeuT structure. These data therefore finally close the door to the possibility of generating a competitive inhibitor of cocaine binding that treats cocaine addiction without itself inhibiting dopamine uptake.
METHODS
Modeling of DAT and ligand complexes. Our modeling protocol is described in detail in the Supplementary Methods online. Briefly, ligands were docked to the LeuT-based model using a simulated annealing-based protocol 18 , implemented in CHARMM 46 . Initial positions were generated with a Monte Carlo algorithm. Parameters for the ligands were generated with structures from the Cambridge Structure Database and ab initio calculations at the HF/6-31G* level. The restrained electrostatic potential-fit method 47 was used to derive the atomic charges. Ligand-transporter interactions were assessed by simulating the complexes in a realistic membrane environment model for B50 ns (Supplementary Methods).
Modeling of chemical cross-links. The Zn 2+ -binding site was modeled in I159C-L80H and the side chains were optimized using the rotameroptimization module of InsightII (Accelrys). Zn 2+ was initially placed in between the Cys-S and His-N atoms and the complex was minimized for 1,000 steps, without any restraints on Zn 2+ . The e-rotameric state of His80 produced the most stable complex. For the BZ-MTS and MTS-3-MTS models, mutants I159C and W84C-I159C were generated in the DAT model, respectively. The structure of BZ-MTS was built in an extended fashion and covalently linked to I159C. Torsional angles of the I159C/BZ-MTS unit were modified to minimize steric overlap with other residues. The MTS-3-MTS molecule was placed in between the rotamer-optimized Cys84 and Cys159 by minimizing the distance between the sulfur atoms of extended MTS-3-MTS and Cys84/Cys159. The BZ-MTS and MTS-3-MTS complexes were minimized to generate the final models.
Molecular biology. Synthetic cDNAs encoding the human DAT (synDAT) and E2C were subcloned into pcDNA3 (Invitrogen) 33 . All mutations were generated by the QuickChange method (Stratagene) and confirmed by DNA sequencing.
Cell culture and transfection. COS7 cells were grown as described previously and transiently transfected with wild-type and mutant constructs using the calcium phosphate-precipitation method 33 .
[ 3 H]Dopamine-uptake experiments. Uptake assays were carried out as described previously 33 CFT in 450 ml of uptake buffer, and the cells were kept at 4 1C. After 1 h, either Zn 2+ (100 mM), MTS-3-MTS (0.5 mM) or BZ-MTS (0.5 mM) were added and the plates were incubated for 10 min at 21 1C before washing twice in uptake buffer (21 1C) . At t ¼ 0, 0.5 ml of uptake buffer (21 1C) with 100 mM CFT (for the Zn 2+ experiments, the uptake buffer also contained 100 mM Zn 2+ ) were added and the reaction was stopped by aspiration of uptake buffer at the indicated time points. Cells were lysed and counted as described previously 30 .
[ 3 H]CFT on-rate experiments. Transfected cells were washed and preincubated with buffer or Zn 2+ (100 mM) before the addition of [ 3 H]CFT. The [ 3 H]CFT incubations were stopped at the indicated time points, washed twice in ice cold uptake buffer, transferred and counted as described previously 30 . Note: Supplementary information is available on the Nature Neuroscience website.
